Windsor James Brian's Form 4 filing
Rein Therapeutics, Inc. (RNTX) · filed May 13, 2026
- Accession no.
- 0001193125-26-220718
- Filed
- May 13, 2026
- Trade date
- Apr 30-May 8, 2026
- Filing delay
- 13 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $25.0K. It was filed 13 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Windsor James BrianCIK 0001790933 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | Common stock , $0.001 par value | PPurchaseAcquired | +25,000 | $1.00 | +$25,000 | 27,046 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | Common Stock | AGrant or awardDisposed | −150,000 | $0.00 | $0 | 150,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
President and Chief Executive Officer